Metformin - Rising PSA Remote Trial (M-RePoRT)

ID Number 14-0472

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology

Description

You are being given information about becoming a volunteer in a research study. You may qualify to participate in this research study because you have been diagnosed with prostate cancer and you have experienced a ‘rising PSA’ also sometimes referred to as biochemical recurrence. Biochemical recurrence means that your prostate-specific antigen (PSA) blood test is rising despite prior surgery or radiation therapy for prostate cancer. This means that the cancer has returned and is growing somewhere in the body, though it is too small to be detected on tests like CT (computed tomography) scans or bone scans.

Metformin is a drug used to treat diabetes, available in the United States since the mid 1990s, and among the most commonly drug taken for diabetes in the world. In the laboratory, metformin has been shown to stop the growth of cancer cells either by working directly on cancer cells or by changing how cancer cells respond to signals from insulin. In studies analyzing diabetic patients with prostate cancer who received metformin, versus other antidiabetic drugs, patients with metformin had a lower risk of recurrence of their cancer and a lower risk of dying from their cancer. These studies were retrospective meaning that researchers looked back to see how prostate cancer behaved in diabetic patients taking metformin versus other antidiabetic drugs and are not definitive proof that metformin can be used to treat prostate cancer. Metformin is currently being evaluated as a potential treatment for many different cancers in clinical trials. In this study, metformin is being evaluated as a treatment for men with prostate cancer and a rising PSA after prior surgery or radiation. Our prior research shows that many patients can’t participate in clinical trials because they live too far away from the study center or the visits are too frequent and burdensome. Therefore, a major goal of the current study is to determine if this clinical trial can be conducted with the majority of ‘visits’ done by telemedicine. Telemedicine means that you will have a monthly video conference from your own home, with the study doctor and team, using a tablet computer provided for use during the study, rather than having to visit the study center for each visit.



Contact Information
Kiev Gimpel-Tetra
(212) 824-7309

Recruiting Patients: Yes